课题基金 / 基金详情

A new approach to quantitative, point-of-care serology

A new approach to quantitative, point-of-care serology
定量、护理点血清学的新方法
批准号:
8708350
负责人:
Kevin W Plaxco
金额:
$34.28万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2014-06-30

项目摘要

项目成果

Kevin W Plaxco的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We have recently demonstrated a reagentless, electrochemical method, termed E-DNA sensors that can detect anti-HIV antibodies in undiluted human serum at levels thousands of times lower than those seen in HIV-positive patient samples. The approach is rapid (sub-10 min), single-step, and quantitative, thus improving significantly on the convenience and/or clinical value of existing molecular diagnostics. It is supported on micron-scale electrodes, and thus can be multiplexed to the level of measuring dozens of diagnostic antibodies in a single finger-prick droplet. Given these attributes, our technology appears well suited for applications that would derive value from the ability to measure quantitative antibody levels or the ability to simultaneously monitor multiple diagnostic antibodies at the point of care or in the field. The focus of the proposed research program is to test this hypothesis by performing the initial, pre-clinical validation of this novel molecular detection platform. Specifically, we will fabricate E-DNA arrays supporting the detection of one to two dozen antibodies diagnostic of a panel of sexually transmitted infections, and perform side-by-side tests of them against a set of gold standard approaches when both are challenged using a large set of authenticated human samples.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biostable nucleic acid aptamers for long-duration, in vivo molecular monitoring
Biostable nucleic acid aptamers for long-duration, in vivo molecular monitoring
Protein-folding-based in-vivo biosensors
Protein-folding-based in-vivo biosensors
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究